Reuters, October 7, 2016. To keep health insurance affordable, companies need to ensure that they are paying for safe and effective treatments, said Diana Zuckerman, president of non-profit organization National Center for Health Research. “When FDA fails to ensure those standards, then ‘FDA approval’ is no longer a gold standard that insurance companies can rely on,” she said.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Anthem Declines to Cover Sarepta Drug for Duchenne, Citing Doubts over Data
STAT News, October 7, 2016. One of the nation’s largest health insurers has decided not to cover a controversial Duchenne muscular dystrophy drug because its FDA approval was not based on scientific evidence that it works. This is what NCHR predicted would happen.
Read More »Obama Extends Controversial Program for Rare Pediatric Drugs
STAT News, September 30, 2016. Friday, President Barack Obama signed into law a bill that will briefly extend a voucher program that rewards drug makers for rare pediatric medicines.
Read More »Does the FDA Have a High Enough Standard for Drug Approvals?
STAT News, September 28, 2016. Is the Food and Drug Administration’s approval process broken? At a HUBweek panel hosted by STAT, experts explored that question in light of the FDA’s decision last week to approve a controversial drug for Duchenne muscular dystrophy, a rare disease.
Read More »Furor Over Drug Prices Puts Patient Advocacy Groups in Bind
The New York Times, September 27, 2016. Public anger over the cost of medical products has burned hot for a year, coursing through social media, popping up on the presidential campaign, and erupting in a series of congressional hearings, including one last week over the rising price of the allergy treatment EpiPen.
Read More »